サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179900

電気診断機器の世界市場-2023-2030

Global Electro-Diagnostic Devices Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
電気診断機器の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

電気診断とは、身体の電気活動の速度や程度を推定する検査技術です。電気診断機器は、筋肉や神経インパルスの電気伝導や電気活動を検査します。これらの機器は、開業医や医師がミオパシー、ニューロパシー、神経筋接合部障害、神経叢障害などの患者に対する診断を推奨するのに役立ちます。主な電気診断には、神経伝導検査（NCS）、体性感覚誘発電位検査（SSEPs）、筋電図（EMG）などがあります。

市場力学

製品イントロダクションの増加、老年人口の増加、関連する慢性疾患は、予測期間中の世界の電気診断機器市場の成長を後押ししています。

製品導入の増加が市場の成長を後押ししています。

市場開拓の増加、老年人口の増加、慢性疾患は、予測期間中の世界の電気診断機器市場の成長を後押ししています。例えば、2020年9月、米国FDA認可の個人用心電図（ECG）技術企業であるAliveCor社は、本日、臨床検証済みの個人用ECGデバイス「KardiaMobile 6L」を導入してインド市場に参入し、世界で唯一の6リード、FDA認可の個人用ECGデバイスで、最もよく見られる3種類の不整脈、心房細動（AFib）、徐脈、頻脈の検出が可能であるとのこと。これらの疾患は定期的なモニタリングが必要なため、患者は自宅でこれらの不整脈を自ら検査することができます。KardiaMobile 6Lは、わずか30秒で医療用心電図を記録することができます。また、2022年10月には、インド初の非接触型遠隔患者モニタリング（RPM）企業であるDozee社が、心血管疾患（CVD）患者をモニタリングするための外来心電図（ECG）パッチの発売を宣言しています。

さらに、2020年7月には、神経学、AI、機械学習など脳に関連する製品やソリューションを提供する医療機器・技術企業のブレインサイエンティフィック社が、使い捨てのEEGヘッドセット「ニューロキャップ」を改良し、新機能を搭載しました。同様に、2022年1月、カドウェルは米国で「Pudendal（Pelvic Floor）Stimulating and Recording Electrode and Cable」を発売しました。スペスメディカ社が製造する陰核電極は、肛門括約筋の陰核神経終末運動潜時（PNTML）を評価するためにSierra Summitシステムと共に開発されたものです。したがって、上記のデータは、製品導入の増加が予測期間中に世界の電気診断機器市場を後押しすることを示しています。

機器の高コストが電気診断機器の世界市場の成長を妨げると予想されます。

しかし、市場成長を阻害する重要な要因の1つは、電気診断機器のセットアップおよび維持コストの高さです。例えば、ハンドヘルド型ECGマシンは500ドル、ラップトップ型ECGマシンは約1000～2000ドルの費用がかかります。同時に、携帯型心電図装置は平均で1000ドルから3000ドルのコストがかかります。

COVID-19の影響。

COVID-19のパンデミックは、世界の電気診断機器市場に中程度の影響を与えました。パンデミックの初期には、COVID-19に大きな焦点が当てられていたため、ほとんどの診断手順が中止または延期されました。しかし、その後COVID-19の症例が減少したため、電気診断の処置は細心の注意を払って行われるようになりました。例えば、2020年初頭、米国では、緊急性のない外来・入院の電気診断（EDx）検査を含む選択的医療処置の中止が確認されました。その後、一部の地域では1日の新規症例数が減少したもの、米国神経筋・電気診断医学会（AANEM）の指導のもと、EDx検査室が再開されました。また、COVID-19を契機に、個人向けモニタリング機器が開発され、市場にプラスの影響を与えました。したがって、COVID-19は世界の電気診断機器市場に様々な影響を与えたと言えます。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 製品上市の増加
      • 慢性疾患の増加
    • 抑制要因
      • デバイスの高コスト
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • 心電図（ECG）
  • 筋電図（EMG）
  • 脳電図（EEG）
  • 神経伝導検査（NCS）
  • 網膜電図（ERG）
  • 胃電図（EGG）

第8章 製品別モビリティ

  • 据え置き型
  • ポータブル

第9章 エンドユーザー別

  • 病院・クリニック
  • 外来手術センター（ASC）
  • 在宅医療
  • 診断センター

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第12章 企業プロファイル

  • GE Healthcare
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Medtronic
  • Abbott
  • Boston Scientific
  • Bionet America, Inc.
  • Philips Healthcare
  • Cardinal Health
  • B. Braun Melsungen AG
  • Stryker Corporation
  • Becton, Dickinson and Company

第13章 DataM

目次
Product Code: DMMD6130

Market Overview

The global electro-diagnostic devices market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Electro-diagnostics is a testing technique that estimates the body's speed or extent of electrical activity. Electro-diagnostics equipment examines muscle and nerve impulses' electrical conduction or activity. These devices help practitioners or physicians recommend diagnoses for patients such as myopathy, neuropathy, neuromuscular junction disorder, and plexopathy. The major electro-diagnostic study includes nerve conduction studies (NCS), somatosensory evoked potential studies (SSEPs), and electromyography (EMG).

Market Dynamics

The rising product introductions, growing geriatric population and associated chronic diseases are boosting the global electro-diagnostic devices market growth in the forecast period.

The increasing product launches are fueling growth in the market.

The increased market developments, growing geriatric population and chronic diseases are boosting the global Electro-Diagnostic Devices market growth in the forecast period. For instance, in September 2020, AliveCor, a US FDA-approved personal electrocardiogram (ECG) technology firm, today entered the Indian market with the introduction of its clinically-validated personal ECG device, KardiaMobile 6L, the world's only six-lead, FDA-cleared personal ECG device and can detect three most common arrhythmias, the atrial fibrillation (AFib), bradycardia, and tachycardia. Since these conditions require regular monitoring, the patients can test themselves for these arrhythmias at home. The KardiaMobile 6L can record a medical-grade ECG in only 30 seconds. Also, in October 2022, Dozee, India's first contactless remote patient monitoring (RPM) company, declared about launching an ambulatory electrocardiogram (ECG) patch to monitor cardiovascular disease (CVD) patients.

Moreover, in July 2020, Brain Scientific Inc., a medical device and technology company delivering products and solutions associated with the brain, including neurology, AI and machine learning, improved its disposable EEG headset, NeuroCap, with new features. Likewise, in January 2022, Cadwell launched the Pudendal (Pelvic Floor) Stimulating and Recording Electrode and Cable in the United States. The pudendal electrode, fabricated by Spes Medica, is developed with the Sierra Summit system to assess pudendal nerve terminal motor latency (PNTML) in the anal sphincter. Therefore, the data above indicates that the increased product introductions boost the global electro-diagnostic devices market during the forecasted period.

The high cost of the equipment is expected to hamper global electro-diagnostic devices market growth.

However, one of the important factors hampering the market growth is the high setup and upkeep costs of electro-diagnostic devices. For instance, handheld ECG machines can be $500, and laptop-based ECG machines cost about $1000-$2,000. At the same time, portable ECG machines cost between $1,000-$3,000 on average.

COVID-19 Impact.

The COVID-19 pandemic moderately impacted the global electro-diagnostic devices market. Most diagnostics procedures were canceled or postponed during the early pandemic day since the major focus was on COVID-19. Still, later with the decrease in cases of COVID-19, electro-diagnosis procedures were performed with extreme precautions. For instance, in early 2020, the cancellation of elective medical procedures in the United States, including non-urgent outpatient and inpatient electro-diagnostic (EDx) studies, was observed. While certain regions subsequently showed a decrease in daily new cases, EDx laboratories were reopened under the direction of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Furthermore, COVID-19 led to the development of personalized monitoring devices which positively impacted the market. Therefore, from the data mentioned, COVID-19 had a mixed impact on the global electro-diagnostic devices market.

Segment Analysis

Electrocardiography (ECG) devices are expected to dominate the electro-diagnostic devices market throughout the forecast period (2022-2029).

Electrocardiography (ECG) product is estimated to hold most of the market share throughout the forecast period. The growing cases of cardiovascular diseases worldwide ensure that the electrocardiography (ECG) devices segment grows at a high CAGR during the forecast period. For instance, according to the WHO, cardiovascular diseases (CVDs) are the major cause of death globally, taking over 17.9 million lives annually. Over 75% of CVD-related deaths happen in low- and middle-income countries. The World Heart Federation forecasts over 23 million CVD-related deaths annually by 2030.

Furthermore, the increased initiatives by various entities to spread awareness about cardiac health are boosting segment growth in the forecasted period. For example, NHLBI, The Heart Truth, and organizations around the United States on National Wear Red Day marked each year on the first Friday in February to obtain greater awareness of heart disease as a leading cause of death for Americans. Also, on February 10, 2019, the Heart Foundation introduced the coordinated advertising and editorial 'Serial Killer' campaign in collaboration with News Corp Australia to point out to Australians that heart disease is the nation's leading cause of death. The campaign delivered Australians with an easy-to-use online tool, the Heart Age Calculator, to enable them to evaluate their own risk for heart disease and called on the Government to support the prevention of heart disease by supplying a Medicare advantage for Heart Health Checks.

Additionally, CDC run Million Hearts is a national endeavor to avert 1 million heart attacks and strokes in the period of five years. It concentrates on enforcing a small set of evidence-based preferences and targets that can enhance cardiovascular health for all. Therefore, from the mentioned data, it is estimated that the electrocardiography (ECG) devices segment will grow at a high CAGR throughout the forecast period.

Geographical Analysis

North America holds the largest market share of global electro-diagnostic devices.

North America is anticipated to hold most of the global electro-diagnostic devices market during the forecasted period (2022-2029) because of the increasing number of developed and well-staffed hospitals and increased healthcare expenditure in this region. For instance, according to the American Hospital Association, currently, over 6,093 hospitals have more than 920,531 staff bed capacity, which in 2022 had over 33,356,853 admissions generating $ 1,213,881,001,000 of expenditure. In addition, the growing geriatric population and related chronic disease cases in this region contribute to the region's dominance over the global electro-diagnostic device market. For example, according to the United States Census Bureau, over 54 million adults ages 65 and older living in the United States in 2021, accounting for around 16.5% of the nation's population. The number of older U.S. adults is growing. By 2050, the total number of adults ages 65 and older is projected to reach 85.7 million, making up around 20% of the overall U.S. population.

Furthermore, according to the CDC, six out of ten U.S. adults have at least one chronic disease. Moreover, according to the same source, approximately 697,000 people in the United States died from heart disease in 2020. The American Heart Association estimated that By 2035 over 130 million U.S. adults will have some heart disease. Thus, the mentioned data indicates that North America will dominate the global electro-diagnostic devices market in the forecast period.

Competitive Landscape

The global electro-diagnostic devices market is fairly consolidated, with selected key players accounting for the predominant market share. The major players with significant market share include Stryker Corporation, Becton, Dickinson and Company, Boston Scientific, Medtronic, Abbot, Bionet America, Inc., Philips Healthcare, Cardinal Health, GE Healthcare, and B. Braun Melsungen AG, among others. The key players focus on R&D, product innovation, and product outreach through distribution through local suppliers and distributors worldwide. For instance, in November 2022, Bionet America, Inc. announced its plan to restructure its diagnostics division to make around 300 million euros in savings by 2025.

GE Healthcare

Overview:

GE Healthcare is headquartered in Chicago, Illinois, United States, and was founded in 2004. It is a subsidiary of the American Multinational Conglomerate General Electric. It is a leading manufacturer and distributor of diagnostic imaging and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

GE Healthcare's product portfolio of electro-diagnostic devices has CARESCAPE B450 Monitor: The CARESCAPE B450 monitor functions seamlessly with the CARESCAPE ONE monitor or CARESCAPE Patient Data Module (PDM) and one additional e-module, delivering the ability to monitor patients with various insights. Portable and inexpensive, it's developed with emergency departments, surgery centers, and step-down units in mind.

The global electro-diagnostic devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches
      • 4.1.1.2. Growing Prevalence of Chronic Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Electrocardiography (ECG)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Electromyogram (EMG)
  • 7.4. Electroencephalography (EEG)
  • 7.5. Nerve Conduction (NCS)
  • 7.6. Electroretinography (ERG)
  • 7.7. Electrogastrography (EGG)

8. By Product Mobility

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 8.1.2. Market Attractiveness Index, By Product Mobility
  • 8.2. Stationary
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Portable

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Homecare
  • 9.5. Diagnostic Centers

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. GE Healthcare
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medtronic
  • 12.3. Abbott
  • 12.4. Boston Scientific
  • 12.5. Bionet America, Inc.
  • 12.6. Philips Healthcare
  • 12.7. Cardinal Health
  • 12.8. B. Braun Melsungen AG
  • 12.9. Stryker Corporation
  • 12.10. Becton, Dickinson and Company

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us